Vericel Corporation (VCEL) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-26

Business type: Treadmill

How it makes money

Vericel earns revenue by selling FDA-approved autologous cell therapies and specialty biologics, driven primarily by demand for its flagship knee cartilage repair product.

Vericel markets two FDA-approved autologous cell therapy products and one specialty biologic product in the U.S. Its primary revenue driver is MACI, an autologous cellularized scaffold product used for repairing full-thickness cartilage defects of the knee in adults. Surgeons purchase accompanying MACI biopsy kits to obtain tissue samples, and subsequently purchase the custom implants and related MACI Arthro instruments.

In addition to knee repair products, it sells Epicel, a permanent skin replacement for severe burns, and holds an exclusive license for NexoBrid, a biological orphan product used for eschar removal in burn care patients.

What protects it: the moat

Vericel protects its market position through exclusive supply agreements, proprietary cell therapy manufacturing processes, and specialized surgical delivery instruments.

Management asserts that the company maintains a highly differentiated portfolio of cell therapy and specialty biologic products combining biology and medical technologies. It secures exclusive access to essential components through agreements such as its long-term supply agreement with Matricel GmbH for ACI-Maix collagen membranes.

Furthermore, the company relies on specialized manufacturing infrastructure located in Cambridge, Massachusetts, and a newly leased facility in Burlington, Massachusetts, alongside proprietary custom-designed arthroscopic instruments developed to support its surgical procedures.

What growth costs

Vericel reinvests earnings by expanding manufacturing capacity, investing in regulatory indication expansions, and funding targeted sales force and international growth initiatives.

The company incurs ongoing capital expenditures and lease commitments to scale its operational footprint, highlighted by its lease for approximately 126,000 square feet of manufacturing, laboratory and office space in Burlington, Massachusetts, intended to become its primary manufacturing facility once validated.

Reinvestment is also directed toward clinical trials and regulatory submissions to expand indications for existing products into additional joints and markets, alongside building out direct sales capabilities and commercializing products such as NexoBrid and MACI Arthro.

What could damage it

An operational disruption or regulatory failure at Vericel's sole manufacturing facility or third-party suppliers would severely limit product supply and impair earnings.

Vericel depends heavily on specialized manufacturing infrastructure and single-source suppliers for critical product components. If the Cambridge manufacturing facility is destroyed or experiences prolonged technical difficulties, or if third-party suppliers such as Matricel or MediWound fail to manufacture and supply essential materials or active ingredients, the company cannot readily substitute production.

Because cell therapies and biologics are subject to stringent regulatory oversight and complex manufacturing specifications, any supply interruption, contamination event, or failure to comply with FDA requirements would immediately restrict commercial distribution and damage financial performance.

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Other companies in Biotechnology